NASDAQ$DTIL
Precision BioSciences Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Precision BioSciences reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Precision BioSciences reported total revenues of $0.6 million for the quarter ended September 30, 2024, compared to $13.1 million for the same period in 2023. Net loss from continuing operations was $16.4 million for the quarter ended September 30, 2024, as compared to a net loss from continuing operations of $12.1 million for the same period in 2023. As of September 30, 2024, Precision had approximately $121.3 million in cash, cash equivalents, and restricted cash.
- Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of chronic hepatitis B; additional global regulatory applications pending approval
- Opened PBGENE-HBV phase 1 clinical program in Moldova; patient screening underway with clinical data expected in 2025
- Strengthened infectious disease capabilities with key clinical talent added to senior leadership team
- Expected cash runway into the second half of 2026 with sufficient capital to phase 1 clinical data for multiple in vivo gene editing programs
Headline financials
Revenue & EPS history
Precision BioSciences · Revenue · Quarterly
$576K
Forward guidance
Precision expects that existing cash and cash equivalents, upfront and potential near-term cash from CAR T transactions, along with expected operational receipts, continued fiscal and operating discipline, and availability of Precision’s at-the-market (ATM) facility are expected to extend Precision’s cash runway into the second half of 2026. Based on its expected cash runway, Precision believes it is sufficiently capitalized to propel two wholly owned programs through Phase 1 data readouts in 2025 and 2026.
Tailwinds
- Cash runway extends into the second half of 2026.
- Sufficient capital to propel two wholly owned programs through Phase 1 data readouts in 2025 and 2026.
- Existing cash and cash equivalents.
- Upfront and potential near-term cash from CAR T transactions.
- Expected operational receipts, continued fiscal and operating discipline, and availability of Precision’s at-the-market (ATM) facility.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-1.6%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-4.3%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+16.4%
Q3 2020
Best reaction
-20.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.4% | +0.8% | — | |
| Q4 2025 | +12.1% | +37.0% | +31.8% | |
| Q3 2025 | -9.8% | -24.8% | -38.0% | |
| Q1 2025 | -8.1% | -1.4% | -1.0% | |
| Q4 2024 | -11.0% | -6.3% | +4.7% | |
| Q3 2024 | -6.2% | -7.1% | -31.5% | |
| Q2 2024 | -2.2% | -8.7% | +14.2% | |
| Q1 2024 | +9.2% | +16.5% | +10.4% | |
| Q4 2023 | +6.4% | -25.4% | -8.3% | |
| Q3 2023 | -1.8% | -5.3% | +1.2% | |
| Q2 2023 | -1.5% | +0.2% | -9.6% | |
| Q1 2023 | -2.4% | -12.2% | -10.9% | |
| Q4 2022 | -20.9% | -22.7% | -31.3% | |
| Q3 2022 | +6.5% | +18.5% | -6.5% | |
| Q2 2022 | -12.1% | +15.5% | -9.2% | |
| Q1 2022 | -4.1% | -18.0% | -6.2% | |
| Q4 2021 | -14.4% | -7.0% | -42.5% | |
| Q3 2021 | +8.9% | +0.7% | -8.8% | |
| Q2 2021 | -3.2% | -10.9% | +20.9% | |
| Q1 2021 | +6.4% | +6.5% | +29.7% | |
| Q4 2020 | -3.9% | -11.4% | -24.0% | |
| Q3 2020 | +16.4% | +32.5% | +1.8% | |
| Q2 2020 | -7.6% | -9.4% | -21.4% | |
| Q1 2020 | +1.2% | +7.1% | +3.7% | |
| Q4 2019 | -9.7% | -14.0% | -12.4% | |
| Q3 2019 | +11.3% | +42.4% | +14.9% | |
| Q2 2019 | -3.7% | +6.4% | +6.9% | |
| Q1 2019 | +2.8% | -6.0% | +6.5% | |
| Q3 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro